We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+11.21%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.61B
AUM Growth
+$95.7M
Cap. Flow
-$7.31M
Cap. Flow %
-0.45%
Top 10 Hldgs %
28.48%
Holding
136
New
14
Increased
29
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
TTD icon
Trade Desk
TTD
+$22.4M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.4M
3
HUBS icon
HubSpot
HUBS
+$14M
4
AIMT
Aimmune Therapeutics
AIMT
+$13.7M
5
APTV icon
Aptiv
APTV
+$13.2M

Top Sells

Rank Stock Value
1
ROL icon
Rollins
ROL
+$21.9M
2
AYI icon
Acuity Brands
AYI
+$17.5M
3
LRCX icon
Lam Research
LRCX
+$14.7M
4
OPLN
Openlane
OPLN
+$13.9M
5
XPO icon
XPO
XPO
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 35.06%
2 Technology 14.25%
3 Consumer Discretionary 14.02%
4 Industrials 8.96%
5 Utilities 4.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
51
Acadia Pharmaceuticals
ACAD
$4.55B
$9.34M 0.58%
334,700
– –
ONCE
52
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$8.96M 0.56%
150,000
– –
KITE
53
DELISTED
Kite Pharma, Inc.
KITE
$8.81M 0.55%
85,000
-43,000
-34% -$3.51M
PANW icon
54
Palo Alto Networks
PANW
$265B
$8.7M 0.54%
390,000
– –
WVE icon
55
Wave Life Sciences
WVE
$1.13B
$8.06M 0.5%
433,500
– –
DBVT
56
DBV Technologies
DBVT
$817M
$7.39M 0.46%
20,700
-1,600
-7% -$546K
SUPN icon
57
Supernus Pharmaceuticals
SUPN
$2.65B
$7.28M 0.45%
169,000
-201,000
-54% -$7.15M
XNCR icon
58
Xencor
XNCR
$1.59B
$7.26M 0.45%
344,000
– –
CERN
59
DELISTED
Cerner Corp
CERN
$7.19M 0.45%
108,200
– –
ALNY icon
60
Alnylam Pharmaceuticals
ALNY
$27.5B
$7.18M 0.45%
90,000
– –
BMRN icon
61
BioMarin Pharmaceuticals
BMRN
$11.7B
$6.81M 0.42%
75,000
– –
PRTA icon
62
Prothena Corp
PRTA
$440M
$6.49M 0.4%
120,000
– –
SAGE
63
DELISTED
Sage Therapeutics
SAGE
$6.45M 0.4%
81,000
– –
MYOV
64
DELISTED
Myovant Sciences Ltd.
MYOV
$6.43M 0.4%
550,000
+255,000
+86% +$3.16M
GWPH
65
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$6.37M 0.4%
63,500
– –
EXR icon
66
Extra Space Storage
EXR
$31.3B
$6.36M 0.4%
81,500
– –
NBIX icon
67
Neurocrine Biosciences
NBIX
$18.7B
$5.75M 0.36%
125,000
– –
RARE icon
68
Ultragenyx Pharmaceutical
RARE
$2.56B
$5.43M 0.34%
87,400
– –
ATHN
69
DELISTED
Athenahealth, Inc.
ATHN
$5.2M 0.32%
37,000
-14,200
-28% -$1.77M
GBT
70
DELISTED
Global Blood Therapeutics, Inc.
GBT
$5.2M 0.32%
190,000
+25,000
+15% +$744K
INCY icon
71
Incyte
INCY
$24.9B
$5.04M 0.31%
40,000
– –
RGEN icon
72
Repligen
RGEN
$8.1B
$4.56M 0.28%
110,000
– –
VRTX icon
73
Vertex Pharmaceuticals
VRTX
$122B
$4.46M 0.28%
34,600
– –
ATRC icon
74
AtriCure
ATRC
$2.04B
$4.37M 0.27%
180,000
– –
BOLD
75
DELISTED
Audentes Therapeutics, Inc
BOLD
$4.3M 0.27%
225,000
– –
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2017 Portfolio in Review

As of Q2 2017, Eventide Asset Management held 136 positions worth $1.61B, up 6.3% from $1.51B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Eventide Asset Management's Q2 2017 filing shows 14 new, 29 increased, 19 reduced and 10 closed positions. Its largest new stake was Trade Desk: 4,900,000 shares worth $24.6M. The largest sale was Rollins, an estimated $21.9M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Eventide Asset Management's largest Q2 2017 buy was Trade Desk: 4,900,000 shares worth $24.6M.
  • Eventide Asset Management added most to AveXis, Inc. Common Stock in Q2 2017, an estimated $19.4M increase.
  • Eventide Asset Management's biggest Q2 2017 reduction was Acuity Brands, cutting an estimated $17.5M.
  • Eventide Asset Management fully exited Rollins in Q2 2017, selling an estimated $21.9M.
  • Eventide Asset Management's ten largest holdings make up 28% of its $1.61B portfolio in Q2 2017.
  • Eventide Asset Management opened 14 new positions and closed 10 in Q2 2017.
  • Eventide Asset Management's portfolio value rose 6.3% quarter-over-quarter to $1.61B.

Based on Eventide Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.